Halozyme To Open New San Francisco Office, Expects To Recruit Talent To Help Commercialize New PEGPH20 Drug

Halozyme Therapeutics, Inc.

, a biotechnology company developing novel oncology and drug-delivery therapies, today announced it will be expanding its facilities by opening a satellite office on Gateway Boulevard in South San Francisco. Halozyme is headquartered in San Diego and currently has approximately 200 employees. "Given the company's focus in oncology and growth trajectory, a satellite office in San Francisco is an important step to help us attract additional talented team members whose focus will be to expand our clinical programs and advance towards our goal of commercializing our investigational new drug, PEGPH20," said Helen Torley, president and CEO. "The Bay Area satellite location will give us the ability to augment our already strong San Diego work force." In addition to the ongoing Phase 2 Study 202 of PEGPH20 in combination with gemcitabine and ABRAXANE® (nab-paclitaxel) in pancreatic cancer, and the Phase 1b/2 study of PEGPH20 in combination with docetaxel in Non-Small Cell Lung Cancer (NSCLC). Halozyme recently announced that it has initiated a clinical trial for a phase 1b/2 study evaluating its investigational new drug PEGPH20 in combination with KEYTRUDA® (pembrolizumab) in NSCLC and Gastric Cancer. Halozyme also plans to initiate a Phase 3 trial of PEGPH20 in combination with gemcitabine and ABRAXANE® (nab-paclitaxel) in pancreatic cancer by the end of Q1 2016. PEGPH20 (PEGylated recombinant human hyaluronidase) targets hyaluronan (HA), a glycosaminoglycan, which is a chain of natural sugars throughout the body that can accumulate around cancer cells, inhibiting other therapies. PEGPH20 is designed to degrade HA to improve the access to tumor cells for chemotherapy, monoclonal antibodies and other immuno-therapy agents. For more information about these studies and other Halozyme news, please visit http://www.halozyme.com/Newsroom.